Fareston use restricted

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the use of Fareston (toremifene) should be restricted.

The CHMP reviewed Fareston due to concerns over its cardiovascular effects, in particular the concern that it could cause prolongation of the QT interval.

The Committee concluded that the benefits of toremifene outweigh its risks for the treatment of hormone-dependent metastatic postmenopausal breast cancer, but that its use should be resricted.

Toremifene should no longer be used in patients with prolonged QT intervals, electrolyte disturbances, clinically relevant bradycardia, heart failure with reduced left-ventricular ejection fraction or a history of symptomatic arrhythmias. In addition, it should not be used with other medicines that prolong the QT interval.

View Fareston drug record

Further information: EMEA Q&A on Fareston review

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Further monthly injectable migraine prophylactic launched

Further monthly injectable migraine prophylactic launched

With the launch of Emgality (galcanezumab), prescribers...

Vitamin D3 Supplements

Formulations and indications of colecalciferol preparations.

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Treatment with febuxostat (Adenuric) should be avoided...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Colestid Orange. Use our constantly updated...